A rising number of women have never been screened for cervical cancer. Here are the risks
A Rising Number of Women Skip Cervical Cancer Screening
Activelifezero.com – A rising number of women in the United States have never received a cervical cancer screening, according to new research that documents a sharp reversal in preventive-care uptake over the past two decades. Cervical cancer remains one of the most preventable malignancies in modern medicine, yet the share of young women who have never undergone a single screening exam has nearly tripled since the mid-2000s. The findings, published on August 27 in JAMA Network Open, reveal that millions of women are going without the basic check that could detect dangerous cellular changes years before they progress to cancer.
What the Survey Data Reveals
Researchers analyzed responses from a nationally representative CDC survey encompassing more than 106,000 women eligible for screening between 2005 and 2023. The trajectory is unambiguous: in 2005, roughly 12.5 percent of American women aged 21 to 29 reported never having been screened. By 2023, that share had climbed to close to 32 percent, translating into approximately 6.2 million young women without a single exam. Among women aged 30 to 65, the never-screened proportion jumped from 5.3 percent in 2005 to nearly 15 percent in 2023, representing about 9.2 million women.
Disparities cut across race, education, and insurance status. In 2023, roughly 44 percent of Asian women aged 21 to 29 said they had never been screened, compared with about 29 percent of White women in the same bracket. Education proved equally decisive: approximately 39 percent of young women holding only a high-school diploma had never been examined, while the figure fell to 17 percent among those with a master’s or doctoral degree. For older women, insurance status was a dividing line — nearly 32 percent of the uninsured had never been screened, versus 11 percent of privately insured women aged 30 to 65.
The Clinical Stakes Behind the Numbers
Dr. Leana Wen, an emergency physician and clinical associate professor at George Washington University who previously served as Baltimore’s health commissioner, contextualized what the statistics mean at the bedside.
Cervical cancer typically develops over many years. More than 9 in 10 cases are caused by persistent infection with certain high-risk types of human papillomavirus.
HPV is extraordinarily common and transmits through intimate skin-to-skin contact, including sexual activity. For most carriers, the immune system clears the virus without lasting damage. In a subset, however, the infection persists and triggers abnormal cellular changes in the cervix. Those changes can evolve from precancerous lesions into invasive cancer over a span of years — precisely the window during which screening can intervene. Women who have never been screened have forfeited that window entirely, and establishing a habit of preventive care in young adulthood tends to set the pattern for later years when risk climbs.
Limitations and Unresolved Questions
The analysis carries important caveats. Screening history was self-reported, so respondents might have misremembered whether or when they had been examined. The study also cannot pinpoint why uptake fell; plausible contributors include reduced access to care, gaps in insurance coverage, personal discomfort with the procedure, and simply not knowing when screening should begin or how often it should repeat. Equally important, the researchers could not establish that the drop in screening directly caused worse cancer outcomes. What they did observe is that among women aged 30 to 64, rates of later-stage cervical cancer rose by more than 2 percent per year after 2017, and among women 65 and older, rates of more advanced disease also trended upward. Those trajectories are alarming, but causation remains unproven.
How Screening Works and What Current Guidance Recommends
Two principal methods exist for cervical cancer screening. The Pap test collects cells from the cervix and examines them under a microscope for precancerous changes or outright cancer. HPV testing, by contrast, detects high-risk HPV types in cervical samples, identifying women at elevated future risk even when cells still appear normal. Depending on age and prior results, guidelines recommend either test alone or a combination at defined intervals, typically every three to five years for women in the 30-to-65 range. The HPV vaccine, available for both sexes, can cut the incidence of certain HPV-linked cancers roughly in half, yet vaccination alone does not replace periodic screening for women already past the vaccination window.
Frequently Asked Questions
How often should I get screened for cervical cancer? For most women aged 30 to 65, current guidelines recommend screening every three to five years using a Pap test, an HPV test, or both combined. Women under 30 generally begin with a Pap test at age 21. Ask your clinician which interval fits your history.
Does the HPV vaccine eliminate the need for screening? No. Vaccination reduces the risk of HPV-linked cancers but does not cover every high-risk type, and it does not treat infections already present. Routine screening remains recommended regardless of vaccination status.
What if I have never been screened and I’m over 30? Schedule an appointment as soon as practical. A single Pap test or HPV test can identify precancerous changes that are fully treatable. The longer the gap since your last exam, the more important it is to close that gap promptly.
Why might screening rates be falling? Contributing factors likely include reduced access to reproductive-health care, insurance gaps, discomfort with the procedure, and confusion about when screening should begin or how frequently it should repeat. No single cause has been confirmed.
